Investigation of a hemophilia family with one female hemophilia A patient and 12 male hemophilia A patients
Annals of Hematology · 26.12.2024
DOI: 10.1007/s00277-024-06158-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Hematology, online erschienen am 26.12.2024. Verfasst von Jie Wang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Shandong Blood Center, Shandong Hemophilia Treatment Center, Jinan, China. Hauptthemen laut MEDLINE: Factor VIII, Hemophilia A. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Shandong Provincial Medical and Health Science and Technology Development Plan.
Abstract (Originalsprache)
Hemophilia A (HA) is an X-chromosome-linked recessive genetic disorder. Female carriers may have bleeding symptoms, but rarely have moderate or severe disease. We identified a female patient with moderate HA by pedigree tracking and genetic testing in a HA family involving consanguineous marriage. To investigate the clinical and laboratory data, as well as F8 genetic variant affecting members in her family. We constructed a detailed pedigree diagram and performed coagulation analyses, including factor VIII activity (FVIII:C), FVIII inhibitor, and von Willebrand factor antigen (VWF: Ag) on 20 family members. The genomic DNA of 11 members was screened for intron 1 and intron 22 inversions using long-distance real-time polymerase chain reaction (RT-PCR). Their F8 coding genes were sequenced with an automatic next-generation sequencing. Thirteen HA persons with hemophilia (12 males, one female) and 18 female carriers were identified in the family. VWF: Ag level was normal in all 13 persons with hemophilia and 7 carriers tested. The female HA patient had FVIII:C 1.9 IU/dL and was homozygous for F8:c.1918G > T:p.V640F. Genetic testing is conducive to the diagnosis of hemophilia carriers and persons with hemophilia. F8: c.1918G > T:p.V640F is the pathogenic HA variant in this family. In any hemophilia family, we need to pay more attention to female carriers and patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shandong Blood Center, Shandong Hemophilia Treatment Center, Jinan, China.
- Central Hospital Affiliated to Shandong First Medical University, Jinan, China.
- Department of Chemistry and Biochemistry, University of California Los Angeles, Los Angeles, CA, USA.
- Cumming School of Medicine, University of Calgary, Calgary, Canada.
- Shandong Blood Center, Shandong Hemophilia Treatment Center, Jinan, China. fyhhbln@163.com.
Förderung
- Shandong Provincial Medical and Health Science and Technology Development Plan
Zitieren
APA
Wang, J., Li, Q., Cheng, Y., Wang, A., Qiao, C., Shao, J., Wang, T., Wang, H., Zhang, X., Poon, M. C., Zhang, X., & Fang, Y. (2024). Investigation of a hemophilia family with one female hemophilia A patient and 12 male hemophilia A patients. Annals of Hematology. https://doi.org/10.1007/s00277-024-06158-0
Vancouver
Wang J, Li Q, Cheng Y, Wang A, Qiao C, Shao J, et al. Investigation of a hemophilia family with one female hemophilia A patient and 12 male hemophilia A patients. Annals of Hematology. 2024. doi:10.1007/s00277-024-06158-0
BibTeX
@article{Wang2024,
author = {Wang, Jie and Li, Qiang and Cheng, Yan and Wang, Aihui and Qiao, Cuicui and Shao, Jingru and Wang, Tiantian and Wang, Hehe and Zhang, Xueqin and Poon, Man-Chiu and Zhang, Xinsheng and Fang, Yunhai},
title = {Investigation of a hemophilia family with one female hemophilia A patient and 12 male hemophilia A patients},
journal = {Annals of Hematology},
year = {2024},
doi = {10.1007/s00277-024-06158-0}
}
EUVIMED